Table 4.
Positive predictive values of CagA and NFATc1 for HPE responsiveness in stage IE/IIE1 gastric MALT lymphoma
| Expression of CagA and NFATc1 molecules in tumor tissue |
Number of patients with gastric MALT lymphoma who received first-line HPE | |
|---|---|---|
| HPE-responsive (n = 59) |
HPE-irresponsive (n = 32) |
|
| CagA positive | 47 | 7 |
| CagA negative | 12 | 25 |
| PPVa for CagA expression = 47 of 54 (87.0%) | ||
| Specificityb for CagA expression = 25 of 32 (78.1%) | ||
| NFATc1 positive | 43 | 8 |
| NFATc1 negative | 16 | 24 |
| PPVa for NFATc1 expression = 43 of 51 (84.3%) | ||
| Specificityb for NFATc1 expression = 24 of 32 (75.0%) | ||
| CagA and NFATc1 are all positive | ||
| Yes | 38 | 4 |
| No | 21 | 28 |
| PPV¶ for combined CagA and NFATc1 = 38 of 42 (90.5%) | ||
| Specificityc for combined CagA and NFATc1 = 28 of 32 (87.5%) | ||
aPositive predictive value (PPV) = Number of HPE-responsive cases who had CagA expression or nuclear NFATc1 localization/Total positive cases for respective CagA expression or nuclear NFATc1 localization
bSpecificity = Number of HPE-irresponsive cases who had no CagA expression or nuclear NFATc1 localization/Total HPE-irresponsive cases
PPV = Number of HPE-responsive cases who had all CagA and nuclear NFATc1 localization/Total cases expressing all CagA and nuclear NFATc1 localization
cSpecificity = Number of HPE-irresponsive cases who did not simultaneously express CagA and nuclear NFATc1 localization in tumors/Total HPE-irresponsive cases
MALT Mucosa-associated lymphoid tissue, HPE Helicobacter pylori eradication